Lv12
30 积分 2025-08-03 加入
Refining the treatment of immune checkpoint inhibitor–associated myocarditis: Challenges, innovations and rechallenge considerations
7小时前
求助中
Effectiveness of Low-Dose Mepolizumab in the Treatment of Eosinophilic Granulomatosis with Polyangiitis (EGPA): A Real-Life Experience
1天前
已完结
Evidence-Based Guideline for the diagnosis and management of eosinophilic granulomatosis with polyangiitis
3天前
已完结
Loeffler’s Endocarditis: An Integrated Multimodality Approach
1个月前
已完结
Characterization of immune checkpoint inhibitor‐induced cardiotoxicity reveals interleukin‐17A as a driver of cardiac dysfunction after anti‐PD‐1 treatment
8个月前
已完结
Immune checkpoint inhibitors mediate myocarditis by promoting macrophage polarization via cGAS/STING pathway
9个月前
已完结
Immune-Checkpoint Inhibitor-Related Myocarditis: Where We Are and Where We Will Go
9个月前
已完结
Immune-checkpoint inhibitor-mediated myocarditis: CTLA4, PD1 and LAG3 in the heart
9个月前
已完结
Clinical Strategy for the Diagnosis and Treatment of Immune Checkpoint Inhibitor–Associated Myocarditis
9个月前
已完结
New Insights into Mechanisms of Immune Checkpoint Inhibitor-Induced Cardiovascular Toxicity
10个月前
已完结
皖公网安备34019202002308
